Source: Okayama University (JAPAN), Public Relations and Information Strategy
For immediate release: 27 February 2019
Okayama University research: Promising biomarker for vascular disease relapse revealed
(Okayama, 27 February) Researchers at Okayama University report in the journal Arthritis & Rheumatology that monitoring a particular antigen can be used for predicting relapse of the vascular disease AAV.
Antibodies are molecules produced by a human’s immune system to counteract bacteria and viruses. When a bacterial or viral pathogenic molecule (a so-called antigen) is detected, an antibody neutralizes it by binding to it. However, autoantibodies are sometimes produced against to our own protein and cause autoimmune diseases. For the autoantibody known as ANCA (antineutrophil cytoplasmic antibody) cause ANCA-associated vasculitis (AAV), at least two antigens exist: proteinase 3 and myeloperoxidase (abbreviated as PR3 and MPO, respectively). Assistant Professor Haruki Watanabe and Associate Professor Ken-Ei Sada from Okayama University and colleagues have now investigated whether MPO-ANCA can be used as a biomarker for the relapse of AAV, a blood-vessel inflammation disease. The researchers’ findings suggest that monitoring MPO-ANCA is useful for predicting relapse in patients with AAV.
The scientists looked at data for 271 MPO-ANCA-positive patients who had achieved remission (disappearance of the signs and symptoms) of AAV during 6 months after therapy was started. Levels of MPO-ANCA were measured at several times in a 2-year period. Assistant Professor Haruki Watanabe and Associate Professor Ken-Ei Sada from Okayama University and colleagues found that for 72% of the patients, MPO-ANCA levels decreased to normal within 6 months after therapy began. MPO-ANCA reappeared for 40% of the patients for which there were complete follow-up data; this reappearance was associated with a relapse occurring simultaneously or later. The researchers therefore concluded that reappearance of MPO-ANCA is a promising marker for AAV relapse.
Assistant Professor Haruki Watanabe and Associate Professor Ken-Ei Sada from Okayama University and colleagues found indications that MPO-ANCA reappearance could be particularly useful as a biomarker for relapse of AAV with kidney involvement (renal AAV). Since only 4 patients without renal involvement experienced relapse, a larger study would be necessary to establish any link between MPO-ANCA reappearance and relapse of non-renal AAV.
The researchers point out that their study has some limitations: the data were obtained earlier, in the context of other investigations, and different participating institutions used different analytic procedures for qualitatively assessing ANCA content. Nevertheless, the study was the largest so far, and also the first with case–control analysis (based on comparisons of patients with and without the disease relapse). Watanabe and colleagues conclude that for patients recovered from MPO-AAV, “routine MPO-ANCA monitoring should be implemented [to predict possible relapse]”.
Background
Antineutrophil cytoplasmic antibody-associated vasculitis
Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) refers to a set of diseases (granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis and microscopic polyangiitis), the characteristics of which are destruction and inflammation of small blood vessels. Clinical signs vary, and different organs can be affected, including kidneys, stomach, and lungs.
A study by Assistant Professor Haruki Watanabe and Associate Professor Ken-Ei Sada from Okayama University and colleagues has now shown that for patients having had AAV, monitoring the presence of an antigen known as MPO-ANCA should help to predict AAV relapse.
Reference
Haruki Watanabe, Ken-Ei Sada, Yoshinori Matsumoto, Masayoshi Harigai, Koichi Amano, Hiroaki Dobashi, Shouichi Fujimoto, Joichi Usui, Kunihiro Yamagata, Tatsuya Atsumi, Shogo Banno, Takahiko Sugihara, Yoshihiro Arimura, Seiichi Matsuo, Hirofumi Makino, For Japan Research Committee of the Ministry of Health Labour,Welfare for Intractable Vasculitis (JPVAS) Research Committee of Intractable Renal Disease of the Ministry of Health Labour, Welfare of Japan. Association Between Reappearance of Myeloperoxidase - Antineutrophil Cytoplasmic Antibody and Relapse in Antineutrophil Cytoplasmic Antibody - Associated Vasculitis: Subgroup Analysis of Nationwide Prospective Cohort Studies. Arthritis & Rheumatology, 2018 Oct;70(10):1626-1633.
DOI: 10.1002/art.40538.
Correspondence to
Assistant Professor Haruki Watanabe, M.D.
Department of Medicine and Clinical Science,
Okayama University Graduate School of Medicine,
Dentistry, and Pharmaceutical Sciences, 2-5-1,
Shikata-cho, Kita-ku, Okayama 700-8558, Japan.
E-mail: harukiw(a)okayama-u.ac.jp
For inquiries, please contact us by replacing (a) with the @ mark.
Further information
Okayama University
1-1-1 Tsushima-naka , Kita-ku , Okayama 700-8530, Japan
Public Relations and Information Strategy
E-mail: www-adm (a) adm.okayama-u.ac.jp
For inquiries, please contact us by replacing (a) with the @ mark.
Website: //www.okayama-u.ac.jp/index_e.html
Okayama Univ. e-Bulletin: //www.okayama-u.ac.jp/user/kouhou/ebulletin/
About Okayama University (You Tube): https://www.youtube.com/watch?v=iDL1coqPRYI
Okayama University Image Movie (You Tube): https://www.youtube.com/watch?v=KU3hOIXS5kk
Okayama University Medical Research Updates （OU-MRU）
The whole volume : OU-MRU (1- )
Vol.1：Innovative non-invasive ‘liquid biopsy’ method to capture circulating tumor cells from blood samples for genetic testing
Vol.2：Ensuring a cool recovery from cardiac arrest
Vol.3：Organ regeneration research leaps forward
Vol.4：Cardiac mechanosensitive integrator
Vol.5：Cell injections get to the heart of congenital defects
Vol.6：Fourth key molecule identified in bone development
Vol.7：Anticancer virus solution provides an alternative to surgery
Vol.8：Light-responsive dye stimulates sight in genetically blind patients
Vol.9：Diabetes drug helps towards immunity against cancer
Vol.10：Enzyme-inhibitors treat drug-resistant epilepsy
Vol.11：Compound-protein combination shows promise for arthritis treatment
Vol.12：Molecular features of the circadian clock system in fruit flies
Vol.13：Peptide directs artificial tissue growth
Vol.14：Simplified boron compound may treat brain tumours
Vol.15：Metamaterial absorbers for infrared inspection technologies
Vol.16：Epigenetics research traces how crickets restore lost limbs
Vol.17：Cell research shows pathway for suppressing hepatitis B virus
Vol.18：Therapeutic protein targets liver disease
Vol.19：Study links signalling protein to osteoarthritis
Vol.20：Lack of enzyme promotes fatty liver disease in thin patients
Vol.21：Combined gene transduction and light therapy targets gastric cancer
Vol.22：Medical supportive device for hemodialysis catheter puncture
Vol.23：Development of low cost oral inactivated vaccines for dysentery
Vol.24：Sticky molecules to tackle obesity and diabetes
Vol.25：Self-administered aroma foot massage may reduce symptoms of anxiety
Vol.26：Protein for preventing heart failure
Vol.27：Keeping cells in shape to fight sepsis
Vol.28：Viral-based therapy for bone cancer
Vol.29：Photoreactive compound allows protein synthesis control with light
Vol.30：Cancer stem cells’ role in tumor growth revealed
Vol.31：Prevention of RNA virus replication
Vol.32：Enzyme target for slowing bladder cancer invasion
Vol.33：Attacking tumors from the inside
Vol.34：Novel mouse model for studying pancreatic cancer
Vol.35：Potential cause of Lafora disease revealed
Vol.36：Overloading of protein localization triggers cellular defects
Vol.37：Protein dosage compensation mechanism unravelled
Vol.38：Bioengineered tooth restoration in a large mammal
Vol.39：Successful test of retinal prosthesis implanted in rats
Vol.40：Antibodies prolong seizure latency in epileptic mice
Vol.41：Inorganic biomaterials for soft-tissue adhesion
Vol.42：Potential drug for treating chronic pain with few side effects
Vol.43：Potential origin of cancer-associated cells revealed
Vol.44：Protection from plant extracts
Vol.45：Link between biological-clock disturbance and brain dysfunction uncovered
Vol.46：New method for suppressing lung cancer oncogene
Vol.47：Candidate genes for eye misalignment identified
Vol.48：Nanotechnology-based approach to cancer virotherapy
Vol.49：Cell membrane as material for bone formation
Vol.50：Iron removal as a potential cancer therapy
Vol.51：Potential of 3D nanoenvironments for experimental cancer
Vol.52：A protein found on the surface of cells plays an integral role in tumor growth and sustenance
Vol.53：Successful implantation and testing of retinal prosthesis in monkey eyes with retinal degeneration
Vol.54：Measuring ion concentration in solutions for clinical and environmental research
Vol.55：Diabetic kidney disease: new biomarkers improve the prediction of the renal prognosis
Vol.56：New device for assisting accurate hemodialysis catheter placement
Vol.57：Possible link between excess chewing muscle activity and dental disease
Vol.58：Insights into mechanisms governing the resistance to the anti-cancer medication cetuximab
Vol.59：Role of commensal flora in periodontal immune response investigated
Vol.60：Role of commensal microbiota in bone remodeling
Vol.61：Mechanical stress affects normal bone development
Vol.62：3D tissue model offers insights into treating pancreatic cancer
0 件のコメント:
コメントを投稿